What is the latest CIPLA stock price?
The latest stored price for CIPLA is Rs 1,432.20 as of 2026-08-21.
gimli
CIPLA stock AI analysis
CIPLA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
CIPLA LTD is a large-cap stock in Healthcare. This Gimli page shows the latest available CIPLA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,432.20
1W return
-1.23%
1M return
-0.02%
3M return
+2.16%
6M return
+6.79%
1Y return
-10.08%
Market cap
₹115,693.19 cr
PE
34.30
PB
3.35
ROE
+10.25%
ROCE
+8.16%
RSI
45.95
Turnover
₹104.30 cr
Why it can matter in screens
- Momentum: CIPLA is below 50DMA, above 200DMA; RSI is 45.95.
- Returns: 1D -0.40%, 1W -1.23%, 1M -0.02%, 3M +2.16%, 1Y -10.08%.
- Trend levels: 52W high ₹1,491.20, 52W low ₹1,341.10, off high -3.96%.
- Liquidity: latest turnover is ₹104.30 cr; volume vs 20D is +0.80%.
- Valuation/profitability: PE 34.30, PB 3.35, ROE +10.25%, ROCE +8.16%.
- Growth: 3Y sales CAGR +7.23%, 3Y profit CAGR +11.45%.
Quick Answers
Is CIPLA above its 50DMA and 200DMA?
CIPLA is below 50DMA, above 200DMA. The latest 50DMA is 1,435.18 and the latest 200DMA is 1,399.40.
What are CIPLA PE, ROE and ROCE?
CIPLA has PE 34.30, ROE +10.25%, and ROCE +8.16% in Gimli's latest available snapshot.
How has CIPLA performed recently?
CIPLA has returned -0.02% over 1 month, +2.16% over 3 months, and -10.08% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 7,077.02 cr | 1,403.20 cr | 789.05 cr | 9.77 |
| 2026-03-31 | 6,464.26 cr | 1,103.11 cr | 554.64 cr | 6.87 |
| 2025-12-31 | 6,962.97 cr | 1,185.49 cr | 675.80 cr | 8.37 |
| 2025-09-30 | 7,858.00 cr | 2,164.00 cr | 1,353.00 cr | 16.72 |
| 2025-06-30 | 6,837.04 cr | 2,036.70 cr | 1,297.62 cr | 16.07 |
| 2025-03-31 | 6,597.72 cr | 1,827.05 cr | 1,221.84 cr | 15.13 |
| 2024-12-31 | 6,961.60 cr | 2,210.53 cr | 1,570.51 cr | 19.45 |
| 2024-09-30 | 6,961.22 cr | 2,076.20 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 27,711.69 cr | 6,355.48 cr | 3,879.23 cr | 43.49 |
| 2025-03-31 | 27,145.40 cr | 7,860.28 cr | 5,272.52 cr | 65.29 |
| 2024-03-31 | 25,446.63 cr | 6,824.05 cr | 4,121.55 cr | 51.05 |
| 2023-03-31 | 22,473.18 cr | 5,152.10 cr | 2,801.91 cr | 34.72 |
| 2022-03-31 | 16,047.52 cr | 4,588.20 cr | 2,882.58 cr | 31.20 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 42,495.98 cr | 1,018.22 cr | 613.77 cr | 34,520.24 cr |
| 2025-03-31 | 37,387.04 cr | 588.69 cr | 438.19 cr | 31,289.25 cr |
| 2024-03-31 | 32,717.82 cr | 640.07 cr | 559.41 cr | 26,802.33 cr |
| 2023-03-31 | 29,463.28 cr | 627.63 cr | 803.12 cr | 23,713.54 cr |
| 2022-03-31 | 27,101.12 cr | 677.74 cr | 1,055.78 cr | 21,117.38 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3,940.02 cr | 860.71 cr | n/a |
| 2025-03-31 | 5,004.98 cr | 3,456.78 cr | n/a |
| 2024-03-31 | 4,133.91 cr | 2,784.61 cr | n/a |
| 2023-03-31 | 3,237.65 cr | 2,054.76 cr | n/a |
| 2022-03-31 | 3,325.90 cr | 2,624.75 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +29.21% | +20.21% | +34.63% | +20.56% | +15.94% | +0.00% |
| 2026-03-31 | +29.21% | +22.56% | +31.97% | +18.66% | +16.25% | +0.00% |
| 2025-12-31 | +29.21% | +23.93% | +30.72% | +19.21% | +16.13% | +0.00% |
| 2025-09-30 | +29.21% | +24.55% | +30.25% | +20.23% | +15.99% | +0.00% |
| 2025-06-30 | +29.19% | +25.25% | +29.26% | +20.44% | +16.30% | +0.00% |
| 2025-03-31 | +29.20% | +26.28% | +28.15% | +20.51% | +16.37% | +0.00% |
| 2024-12-31 | +29.19% | +26.65% | +27.71% | +20.46% | +16.44% | +0.00% |
| 2024-09-30 | +30.92% | +28.80% | +24.16% | +17.48% | +16.11% | +0.00% |
| 2024-06-30 | +30.91% | +27.81% | +24.95% | +17.62% | +16.33% | +0.00% |
| 2024-03-31 | +33.47% | +25.83% | +24.42% | +16.83% | +16.28% | +0.00% |
| 2023-12-31 | +33.47% | +25.73% | +24.33% | +16.66% | +16.46% | +0.00% |
| 2023-09-30 | +33.47% | +25.74% | +24.18% | +16.48% | +16.60% | +0.00% |
| 2023-06-30 | +33.47% | +25.49% | +24.33% | +15.35% | +16.69% | n/a |
| 2023-03-31 | +33.55% | +27.42% | +22.10% | +15.00% | +16.94% | +0.00% |
| 2022-12-31 | +33.61% | +28.39% | +21.13% | +14.09% | +16.87% | +0.00% |
| 2022-09-30 | +33.61% | +27.69% | +21.73% | +13.78% | +16.97% | +0.00% |
| 2022-06-30 | +33.61% | +0.00% | +48.98% | n/a | n/a | +0.00% |
| 2022-03-31 | +33.63% | +0.00% | +48.64% | n/a | n/a | +0.00% |
| 2021-12-31 | +36.11% | +0.00% | +45.88% | n/a | n/a | +0.00% |
| 2021-09-30 | +36.12% | +0.00% | +45.83% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
| DRREDDY | DR. REDDY S LABORATORIES | 97,804.91 cr | 29.535819 | +9.23% | -7.98% |
Try these prompts
- Analyze CIPLA with valuation, momentum and industry peers
- Compare CIPLA with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare CIPLA with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.